RISFAX July 18, 2018
日本語- Teva Takeda: Recall of “Valsartan” by Teva of Israel, no impact on Japan
- Chugai and Roche enter into license agreement for “Entrectinib” designated for Sakigake fast-track review
- Japan Council for Quality Health Care calls for attention to cases of administering excessive total dose of cancer drugs
- Astellas: FDA approves additional indication of “XTANDI” for non-metastatic (CRPC)
- Three (3) pharmaceutical universities, Meiji, Hoshi and Kyoto, collaborate for developing pharmacists
- Mochida and Sumitomo Dainippon’s subsidiary initiate “EPADEL” clinical study in China
- Ministry of Finance (MOF) appointment: Mr. Yoshino becomes budget examiner in charge of medical and nursing care, etc.
- Japan Association of Chain Drug Stores: Mr. Imanishi, former president of Tokyo University of Pharmacy and Life Sciences, becomes secretary-general
- ARKRAY starts shipment of urinalysis device produced at Russian plant